# SCI Engineered Materials, Inc.: financial statements, quarterly

SCIA · OTC · CIK 830616 · [Technology](/sectors/technology.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/scia.md) · [Financials](/companies/scia/financials.md) · [Filings](/companies/scia/filings.md) · [Insiders](/companies/scia/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/scia/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $k | [7,700](/filings/0001558370-24-014084.md) | [7,029 d](/filings/0001558370-25-000969.md) | [8,403](/filings/0001558370-25-006147.md) | [5,533](/filings/0001558370-25-009931.md) | [3,883](/filings/0001104659-25-104659.md) | [5,051 d](/filings/0001104659-26-015820.md) | [3,500](/filings/0001104659-26-053487.md) | [3,609](/filings/0001104659-26-088472.md) | [5,289](/filings/0001104659-25-104659.md) | [7,207 d](/filings/0001104659-26-015820.md) | [8,160](/filings/0001104659-26-053487.md) | [9,485](/filings/0001104659-26-088472.md) |
| Cost of revenue | $k | [6,313](/filings/0001558370-24-014084.md) | [5,742 d](/filings/0001558370-25-000969.md) | [6,988](/filings/0001558370-25-006147.md) | [4,154](/filings/0001558370-25-009931.md) | [2,794](/filings/0001104659-25-104659.md) | [3,866 d](/filings/0001104659-26-015820.md) | [2,427](/filings/0001104659-26-053487.md) | [2,451](/filings/0001104659-26-088472.md) | [3,958](/filings/0001104659-25-104659.md) | [5,738 d](/filings/0001104659-26-015820.md) | [6,125](/filings/0001104659-26-053487.md) | [7,209](/filings/0001104659-26-088472.md) |
| Gross profit | $k | [1,387](/filings/0001558370-24-014084.md) | [1,287 d](/filings/0001558370-25-000969.md) | [1,415](/filings/0001558370-25-006147.md) | [1,379](/filings/0001558370-25-009931.md) | [1,089](/filings/0001104659-25-104659.md) | [1,185 d](/filings/0001104659-26-015820.md) | [1,073](/filings/0001104659-26-053487.md) | [1,158](/filings/0001104659-26-088472.md) | [1,331](/filings/0001104659-25-104659.md) | [1,469 d](/filings/0001104659-26-015820.md) | [2,035](/filings/0001104659-26-053487.md) | [2,276](/filings/0001104659-26-088472.md) |
| Research and development | $k | [122](/filings/0001558370-24-014084.md) | [130 d](/filings/0001558370-25-000969.md) | [185](/filings/0001558370-25-006147.md) | [175](/filings/0001558370-25-009931.md) | [130](/filings/0001104659-25-104659.md) | [74.7 d](/filings/0001104659-26-015820.md) | [102](/filings/0001104659-26-053487.md) | [107](/filings/0001104659-26-088472.md) | [111](/filings/0001104659-25-104659.md) | [114 d](/filings/0001104659-26-015820.md) | [143](/filings/0001104659-26-053487.md) | [147](/filings/0001104659-26-088472.md) |
| Operating income | $k | [710](/filings/0001558370-24-014084.md) | [545 d](/filings/0001558370-25-000969.md) | [618](/filings/0001558370-25-006147.md) | [585](/filings/0001558370-25-009931.md) | [359](/filings/0001104659-25-104659.md) | [482 d](/filings/0001104659-26-015820.md) | [303](/filings/0001104659-26-053487.md) | [356](/filings/0001104659-26-088472.md) | [540](/filings/0001104659-25-104659.md) | [631 d](/filings/0001104659-26-015820.md) | [489](/filings/0001104659-26-053487.md) | [1,399](/filings/0001104659-26-088472.md) |
| Interest expense | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Income tax | $k | [213](/filings/0001558370-24-014084.md) | [71.5 d](/filings/0001558370-25-000969.md) | [160](/filings/0001558370-25-006147.md) | [155](/filings/0001558370-25-009931.md) | [106](/filings/0001104659-25-104659.md) | [156 d](/filings/0001104659-26-015820.md) | [91.0](/filings/0001104659-26-053487.md) | [107](/filings/0001104659-26-088472.md) | [150](/filings/0001104659-25-104659.md) | [186 d](/filings/0001104659-26-015820.md) | [136](/filings/0001104659-26-053487.md) | [340](/filings/0001104659-26-088472.md) |
| Net income | $k | [579](/filings/0001558370-24-014084.md) | [566 d](/filings/0001558370-25-000969.md) | [545](/filings/0001558370-25-009931.md) | [527](/filings/0001558370-25-009931.md) | [361](/filings/0001104659-25-104659.md) | [429 d](/filings/0001104659-26-015820.md) | [310](/filings/0001104659-26-088472.md) | [364](/filings/0001104659-26-088472.md) | [510](/filings/0001104659-25-104659.md) | [561 d](/filings/0001104659-26-015820.md) | [462](/filings/0001104659-26-088472.md) | [1,170](/filings/0001104659-26-088472.md) |
| Diluted EPS | $ per share | [0.13](/filings/0001558370-24-014084.md) | not reported | [0.12](/filings/0001558370-25-006147.md) | [0.12](/filings/0001558370-25-009931.md) | [0.08](/filings/0001104659-25-104659.md) | not reported | [0.07](/filings/0001104659-26-053487.md) | [0.08](/filings/0001104659-26-088472.md) | [0.11](/filings/0001104659-25-104659.md) | not reported | [0.10](/filings/0001104659-26-053487.md) | [0.26](/filings/0001104659-26-088472.md) |
| Basic EPS | $ per share | [0.13](/filings/0001558370-24-014084.md) | not reported | [0.12](/filings/0001558370-25-006147.md) | [0.12](/filings/0001558370-25-009931.md) | [0.08](/filings/0001104659-25-104659.md) | not reported | [0.07](/filings/0001104659-26-053487.md) | [0.08](/filings/0001104659-26-088472.md) | [0.11](/filings/0001104659-25-104659.md) | not reported | [0.10](/filings/0001104659-26-053487.md) | [0.26](/filings/0001104659-26-088472.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: not reported
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [5.8](/filings/0001558370-23-016905.md) | [5.7](/filings/0001558370-25-000969.md) | [5.5](/filings/0001558370-24-006595.md) | [6.2](/filings/0001558370-24-010649.md) | [7.7](/filings/0001558370-24-014084.md) | [6.8](/filings/0001104659-26-015820.md) | [7.4](/filings/0001558370-25-006147.md) | [8.0](/filings/0001558370-25-009931.md) | [9.5](/filings/0001104659-25-104659.md) | [7.9](/filings/0001104659-26-088472.md) | [8.5](/filings/0001104659-26-053487.md) | [9.9](/filings/0001104659-26-088472.md) |
| Current assets | $m | [12.5](/filings/0001558370-23-016905.md) | [13.6](/filings/0001558370-25-000969.md) | [11.0](/filings/0001558370-24-006595.md) | [10.5](/filings/0001558370-24-010649.md) | [11.6](/filings/0001558370-24-014084.md) | [9.7](/filings/0001104659-26-015820.md) | [9.9](/filings/0001558370-25-006147.md) | [9.9](/filings/0001558370-25-009931.md) | [13.6](/filings/0001104659-25-104659.md) | [10.2](/filings/0001104659-26-088472.md) | [13.1](/filings/0001104659-26-053487.md) | [15.7](/filings/0001104659-26-088472.md) |
| Total assets | $m | [16.1](/filings/0001558370-23-016905.md) | [17.5](/filings/0001558370-25-000969.md) | [15.4](/filings/0001558370-24-006595.md) | [14.9](/filings/0001558370-24-010649.md) | [16.7](/filings/0001558370-24-014084.md) | [15.5](/filings/0001104659-26-015820.md) | [15.9](/filings/0001558370-25-006147.md) | [16.6](/filings/0001558370-25-009931.md) | [20.5](/filings/0001104659-25-104659.md) | [17.3](/filings/0001104659-26-088472.md) | [20.2](/filings/0001104659-26-053487.md) | [22.8](/filings/0001104659-26-088472.md) |
| Current liabilities | $m | [5.4](/filings/0001558370-23-016905.md) | [5.9](/filings/0001558370-25-000969.md) | [3.2](/filings/0001558370-24-006595.md) | [2.3](/filings/0001558370-24-010649.md) | [3.0](/filings/0001558370-24-014084.md) | [1.5](/filings/0001104659-26-015820.md) | [1.5](/filings/0001558370-25-006147.md) | [1.9](/filings/0001558370-25-009931.md) | [5.2](/filings/0001104659-25-104659.md) | [1.9](/filings/0001104659-26-088472.md) | [4.5](/filings/0001104659-26-053487.md) | [5.7](/filings/0001104659-26-088472.md) |
| Total liabilities | $m | [5.6](/filings/0001558370-23-016905.md) | [6.5](/filings/0001558370-25-000969.md) | [3.8](/filings/0001558370-24-006595.md) | [2.8](/filings/0001558370-24-010649.md) | [4.2](/filings/0001558370-24-014084.md) | [2.6](/filings/0001104659-26-015820.md) | [2.7](/filings/0001558370-25-006147.md) | [3.0](/filings/0001558370-25-009931.md) | [6.3](/filings/0001104659-25-104659.md) | [3.1](/filings/0001104659-26-088472.md) | [5.8](/filings/0001104659-26-053487.md) | [7.2](/filings/0001104659-26-088472.md) |
| Shareholders' equity | $m | [10.4](/filings/0001558370-24-014084.md) | [11.0](/filings/0001104659-26-015820.md) | [11.6](/filings/0001558370-25-009931.md) | [12.1](/filings/0001104659-25-104659.md) | [12.5](/filings/0001104659-25-104659.md) | [12.9](/filings/0001104659-26-088472.md) | [13.2](/filings/0001104659-26-088472.md) | [13.6](/filings/0001104659-26-088472.md) | [14.1](/filings/0001104659-25-104659.md) | [14.2](/filings/0001104659-26-088472.md) | [14.5](/filings/0001104659-26-088472.md) | [15.6](/filings/0001104659-26-088472.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [900 d](/filings/0001558370-24-014084.md) | [(47.3) d](/filings/0001558370-25-000969.md) | [(11.7)](/filings/0001558370-25-006147.md) | [859 d](/filings/0001558370-25-009931.md) | [1,563 d](/filings/0001104659-25-104659.md) | [(40.3) d](/filings/0001104659-26-015820.md) | [933](/filings/0001104659-26-053487.md) | [990 d](/filings/0001104659-26-088472.md) | [1,761 d](/filings/0001104659-25-104659.md) | [(384) d](/filings/0001104659-26-015820.md) | [1,178](/filings/0001104659-26-053487.md) | [1,911 d](/filings/0001104659-26-088472.md) |
| Capital expenditure | $k | [184 d](/filings/0001558370-24-014084.md) | [55.3 d](/filings/0001558370-25-000969.md) | [177](/filings/0001558370-25-006147.md) | [111 d](/filings/0001558370-25-009931.md) | [91.0 d](/filings/0001104659-25-104659.md) | [121 d](/filings/0001104659-26-015820.md) | [83.3](/filings/0001104659-26-053487.md) | [132 d](/filings/0001104659-26-088472.md) | [205 d](/filings/0001104659-25-104659.md) | [585 d](/filings/0001104659-26-015820.md) | [327](/filings/0001104659-26-053487.md) | [561 d](/filings/0001104659-26-088472.md) |
| Share repurchases | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | [268](/filings/0001104659-26-053487.md) | [0.0 d](/filings/0001104659-26-088472.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | thousands of shares | [4,545](/filings/0001558370-23-016905.md) | [4,555](/filings/0001558370-24-006595.md) | [4,560](/filings/0001558370-24-010649.md) | [4,562](/filings/0001558370-24-014084.md) | [4,568](/filings/0001558370-25-006147.md) | [4,569](/filings/0001558370-25-009931.md) | [4,569](/filings/0001104659-25-104659.md) | [4,572](/filings/0001104659-26-053487.md) | [4,579](/filings/0001104659-26-088472.md) | [4,583](/filings/0001104659-25-104659.md) | [4,470](/filings/0001104659-26-053487.md) | [4,450](/filings/0001104659-26-088472.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 4,450,003 at 2026-07-30, from the cover of the [10-Q filed 2026-07-30](/filings/0001104659-26-088472.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:25 ET. No prices; not investment advice.